SWM
IOVA icon

SeaCrest Wealth Management’s Iovance Biotherapeutics IOVA Stock Holding History

SeaCrest Wealth Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-20,406
Closed -$192K – 679
2024
Q3 		$192K Sell
20,406
-1,277
-6% -$12.1K 0.02% 621
2024
Q2 		$174K Buy
+21,683
New +$232K 0.02% 586

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

SeaCrest Wealth Management's IOVA Position: Q4 2024 in Review

SeaCrest Wealth Management sold out of Iovance Biotherapeutics (IOVA) in Q4 2024, closing a stake of 20,406 shares — an estimated $192K sold.

SeaCrest Wealth Management first reported a position in IOVA in Q2 2024 and held it in 2 quarters. The position peaked at $192K in Q3 2024. 301 funds tracked by Wall St. Rank hold IOVA as of Q4 2024.

  • SeaCrest Wealth Management reported no remaining Iovance Biotherapeutics position as of Q4 2024 after selling out during the quarter.
  • SeaCrest Wealth Management sold 20,406 Iovance Biotherapeutics shares in Q4 2024, an estimated $192K.
  • SeaCrest Wealth Management first reported a position in Iovance Biotherapeutics in Q2 2024 and held it in 2 quarters.
  • SeaCrest Wealth Management's Iovance Biotherapeutics position peaked at $192K in Q3 2024.
  • 301 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2024.

Based on SeaCrest Wealth Management's 13F filing for Q4 2024, filed 14 Jan 2025.